This startup provides bioinformatics solutions for drug discovery and development, focusing on personalized and precision therapies. Their services include CRISPR/siRNA selection, customized reference genomes, target discovery, and mechanism of action identification, helping healthcare firms accelerate drug development for cancers and rare diseases.
Funding
Funding not disclosed
Founders
Product
Problem
The development of personalized and precision therapies is hindered by the complexity of identifying optimal drug targets and understanding their mechanisms of action, particularly in cancers and rare diseases. Traditional bioinformatics approaches often lack the specificity and customization needed to effectively leverage genomic data for drug discovery.
Solution
This startup offers tailored bioinformatics solutions designed to accelerate drug discovery and development for personalized medicine. They provide services that enable precise CRISPR/siRNA selection, facilitating targeted gene editing and knockdown experiments. The company also specializes in creating customized reference genomes, allowing researchers to analyze genomic data with greater accuracy and relevance to specific patient populations or disease subtypes. Furthermore, they offer target discovery services to identify novel therapeutic targets and elucidate their mechanisms of action, providing insights into disease pathways and potential drug interventions.
Target Audience
The primary customers are healthcare firms and research institutions involved in drug discovery and development, particularly those focused on personalized and precision therapies for cancers and rare diseases.
Features
- CRISPR/siRNA selection for targeted gene editing and knockdown
- Customized reference genomes tailored to specific patient populations or disease subtypes
- Target discovery services to identify novel therapeutic targets
- Mechanism of action identification to elucidate disease pathways and potential drug interventions